GSK3 alpha antibody
Principal name
GSK3 alpha antibody
Alternative names for GSK3 alpha antibody
Glycogen synthase kinase-3 alpha, GSK3A, GSK-3 alpha, Factor A
Ncbi ID
NP_063937.2, NP_063937, 9606, NM_019884, NP_001026837.1, NM_001031667
Available reactivities
Available hosts
Available applications
Western blot / Immunoblot (WB), Paraffin Sections (P), Enzyme Immunoassay (E), Immunocytochemistry/Immunofluorescence (ICC/IF), Immunoprecipitation (IP), Frozen Sections (C)
Background of GSK3 alpha antibody
Glycogen synthase kinase 3-alpha (GSK3A)is a multifunctional protein serine kinase implicated in the control of several regulatory proteins including glycogen synthase and transcription factors. It also plays a role in the WNT and PI3K signaling pathways.1 Under resting conditions GSK3A and its homologs are highly phosphorylated at tyr279 in the phosphorylation loop.2 Constitutive phosphorylation of this tyrosine is important for kinase activity. Dephosphorylation of tyr279 after mitogen activation is accompanied by kinase inactivation. PKA as well as PI3K-activated PKB inactivate GSK3A by phosphorylation at ser21.3 Lysophosphatidic acid primarily utilizes a PKC-dependent pathway to modulate GSK3 and certain growth factors (e.g., PDGFB), which control GSK3 mainly through PIK3-PKB, are able to regulate GSK3 through an alternative, redundant phospholipase-C-gamma-PKC pathway.4 Alzheimer disease (AD) is associated with increased production and aggregation of amyloid-beta-40 and -42 peptides into plaques. GSK3A is required for maximal production of the beta-amyloid-40 and -42 peptides generated from the amyloid precursor protein (APP) by presenilin (PSEN1)-dependent gamma-secretase cleavage.5 In vitro, lithium, a GSK3A inhibitor, blocked the production of the beta-amyloid peptides by interfering with the gamma-secretase step. In mice expressing familial AD-associated mutations in APP and PSEN1, lithium reduced the levels of beta-amyloid peptides GSK3A also phosphorylates the tau protein (MAPT), the principal component of neurofibrillary tangles in AD, and suggested that inhibition of GSK3A may offer a new therapeutic approach to AD.
General readings
1. Darrington RS et al. Distinct expression and activity of GSK-3a and GSK-3ß in prostate cancer. Int J Cancer 131:E872-83 (2012).
2. Campa VM & Kypta RM Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells. Biol Direct 6:4 (2011). WB, ICC/IF ; Human .
3. Lauing KL et al. Exogenous Activation of Wnt/ß-Catenin Signaling Attenuates Binge Alcohol-Induced Deficient Bone Fracture Healing. Alcohol Alcohol N/A:N/A (2014). Mouse .
4. Durak O et al. Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of ß-catenin. Mol Psychiatry N/A:N/A (2014).
5. Shanmugam V et al. Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer. BMC Med Genomics7:36 (2014). WB .
6. Jin R et al. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of ß-catenin through mechanisms involving FRAT1 and PAK4. J Cell Sci127:3116-30 (2014). Human .
7. Rui Y et al. Activity-dependent regulation of dendritic growth and maintenance by glycogen synthase kinase 3ß. Nat Commun 4:2628 (2013).
8. Marques JM et al. CRMP2 tethers kainate receptor activity to cytoskeleton dynamics during neuronal maturation. J Neurosci 33:18298-310 (2013).
9. Ohmi K et al. Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B. PLoS One 6:e27461 (2011). IHC-Fr ; Mouse .
10. Ramirez SH et al. Inhibition of glycogen synthase kinase 3beta (GSK3beta) decreases inflammatory responses in brain endothelial cells. Am J Pathol 176:881-92 (2010). IHC-Fr ; Human .
Detection of endogenous GSK3alpha Whole cell lysates of serum starved tumor cells (20.000 cells per lane) were applied to SDS-PAGE and transferred to a PVDF membrane. The immunoblot was probed with mab GSK3a-10C1 (0.5 µg/ ml) for 1h at RT and developed by ECL (exp. time: 30 sec).Lane 1: A431 Lane 2: A549 Lane 3: SKOV-3 Lane 4: OVCAR-5Lane 5: HaCaT Lane 6: PC3MLane 7: HelaLane 8: HepG2
Phosphospecificity Whole cell extracts of control (co), EGF stimulated (EGF) or pervanadate treated (VH) A431 tumor cells were applied to SDS-PAGE (ca 20.000 cells per lane) and transferred to PVDF membranes. Immunoblots were probed with mab GSK-9B8 (0.5 µg/ ml) for 1h at RT and developed by ECL (exp. time: 30 sec).
Human HepG2; WB Suggested Anti-GSK3A Antibody Titration: 1.25ug/ml. Positive Control: HepG2 cell lysate. GSK3A is strongly supported by BioGPS gene expression data to be expressed in Human HepG2 cells.; GSK3A antibody - N-terminal region (AVARP01028_T100) in Human HepG2 cells using Western Blot
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using GSK3alpha (pSer21) Antibody (left) or the same Antibody preincubated with blocking peptide (right)
Immunofluorescence staining of methanol-fixed HeLa cells showing cytoplasmic staining using GSK3alpha (pSer21) Antibody
Western Blot analyss of extracts from 293 cells untreated (lane1) or treated with serum (lane2) using GSK3alpha (pSer21) Antibody
Immunohistochemical analysis of paraffin- embedded human breast carcinoma tissue using GSK3α antibody (AP02551PU-S; AP02551PU-N).
Immunofluorescence staining of methanol fixed MCF7 cells using GSK3 alpha antibody
Western Blot analysis of extracts from 293 cells using GSK3alpha antibody
Western blot analysis of extracts from ovary cancer cells using GSK3α antibody (AP02551PU-S; AP02551PU-N)
Immunohistochemistry (IHC) analyzes of GSK3α antibody (Cat.-No.: AP06151PU-N) in paraffin-embedded human breast carcinoma tissue.
Western blot (WB) analysis of GSK3α antibody (Cat.-No.: AP06151PU-N) at 1/500 dilution
Lane1:Hela cell lysate
Lane2:Raw264.7 cell lysate
Lane3:PC12 cell lysate
Lane1:Hela cell lysate
Lane2:Raw264.7 cell lysate
Lane3:PC12 cell lysate
Proteins were resolved from MCF-7 cell extracts by SDS-PAGE. The proteins were transferred to PVDF membrane and incubated with 0.5 μg/mL of the Mouse monoclonal anti-GSK-3α/β antibody.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using GSK3A polyclonal antibody ( Cat # PAB5378 ) .
Western blot analysis of extracts from ovary cancer cells , using GSK3A polyclonal antibody ( Cat # PAB5378 ) .
GSK3A monoclonal antibody, clone MS-1G7 ( Cat # MAB0989 ). Western blot analysis of GSK3A in Jurkat.
Immunohistochemistry (IHC) analysis of GSK3a pSer21 Antibody (Cat.-No.: AP01594PU-N) in paraffin-embedded human breast carcinoma tissue.
Western blot (WB) analysis of GSK3a pSer21 antibody (Cat.-No.: AP01594PU-N) in extracts from ovary cancer.
Human brain stained with Anti-GSK-3 antibody
Western blot using GSK3A (phospho S21) polyclonal antibody ( Cat # PAB10054 ) shows detection of a 52 kDa band corresponding to human GSK3A in various human derived 293T cell extracts.Cells were serum starved for 24 h.Lane 1 : control, Lane 2: treated with IGF-1 ( 100 ng/ml ) for 20 min, Lane 3 : pre-treated with 10 µM PI3K inhibitor and treated with IGF-1 ( 100 ng/ml ) for 20 min.Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation ( lane2 ) and diminished when aninhibitor is added ( lane 3 ).Approximately 20 µg of lysate was run on a SDS-PAGE and transferred onto nitrocel followed by reaction with a 1:1,000 dilution of anti-GSK3A antibody.Signal was detected using standard techniques.Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.
Immunohistochemical staining of GSK3A/GSK3B on formalin fixed, paraffin embedded human brain with GSK3A/GSK3B polyclonal antibody.
The NIH/3T3 cell lysate derived from conditioned culture medium was resolved onto 10% SDS-PAGE, transferred onto NC membrane, and followed by an immunoblotting with GSK3A ( phospho S21 ) polyclonal antibody ( Cat # PAB12623 ) at 1 : 500 ( lane 1 ). Lane 2 was pre-incubated with immunizing peptide.
The NIH/3T3 cell lysate was resolved onto 10% SDS-PAGE, transferred onto NC membrane, and followed by an immunoblotting with GSK3A polyclonal antibody ( Cat # PAB12687 ) at 1 : 500 ( lane 1 ). Lane 2 was pre-incubated with immunizing peptide.
Immunohistochemical analysis of paraffin-embedded human lung carcinoma ( A ) and skin carcinoma ( B ) tissue, showing cytoplasmical localization, using GSK3A monoclonal antibody, clone 6G2F1, 6G2F2 ( Cat # MAB5585 ) with DAB staining.
Western blot analysis using GSK3A monoclonal antibody, clone 6G2F1, 6G2F2 ( Cat # MAB5585 ) against truncated GSK3A recombinant protein ( Lane 1 ) and A-549 ( Lane 2 ) cell lysates.
Detection of endogenous GSK3b pTyr215, GSK3a pTyr278: Whole cell lysates of serum starved tumor cells (20.000 cells per lane) were applied to SDS-PAGE and transferred to PVDF membranes. Immunoblots were probed with AM20216PU-N GSK3alpha/beta antibody (Clone 6D3) at 0.5 µg/ ml for 1h at RT and developed by ECL (exp. time: 30 sec).Lane 1: HeLa Lane 2: HepG2 Lane 3: HEK293 Lane 4: SH-SY5YLane 5: MDCK Lane 6: PC12; Lane 7: CMT 93 Lane 8: Neuro 2ALane 9: 3T3
Immunohistochemistry Analysis: AP20202PU-N GSK3a/b antibody staining of Paraffin-Embedded Human breast carcinoma tissue.
Western blot (WB) analysis of GSK3a/b antibody (Cat.-No.: AP20202PU-N) in extracts from 293 cells treated with TNF-a 20ng/ml 30mins.
Immunohistochemistry (IHC) analyzes of p-GSK3alpha antibody (Cat.-No.. AP20890PU-N) in paraffin-embedded human breast carcinoma tissue.
Western blot (WB) analysis of p-GSK3alpha antibody (Cat.-No.: AP20890PU-N) in extracts from ovary cancer.
Immunohistochemistry (IHC) analyzes of GSK3alpha pAb in paraffin-embedded human breast carcinoma tissue.
Western blot (WB) analyzes of GSK3alpha pAb in extracts from CV-1 cells.
Immunofluorescence analysis of Hela cells using GSK3 alpha antibody Cat.-No AM06171SU-N showing cytoplasmic localization.
Western blot analysis using GSK3 alpha antibody Cat.-No AM06171SU-N against Hela (1) and PC-3 cell lysate.
Western blot analysis using GSK3 alpha antibody Cat.-No AM06172SU-N against truncated GSK3 alpha recombinant protein (Lane 1) and Hela cell lysate (lane 2).
Immunohistochemical analysis of GSK3 alpha (pS21) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
Immunofluorescent analysis of GSK3 alpha (pS21) staining in PC12 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).
Western blot analysis of GSK3 alpha (pS21) expression in HEK293T UV-treated (A); mouse liver (B); rat liver (C); PC12 H2O2-treated (D) whole cell lysates.
Immunohistochemical analysis of GSK3 alpha/beta staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
Western blot analysis of GSK3 alpha/beta expression in HEK293T (A); mouse liver (B); PC12 (C) whole cell lysates.
Immunohistochemical analysis of GSK3 alpha/beta (pY279/216) staining in human lung cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
Western blot analysis of GSK3 alpha/beta (pY279/216) expression in A549 insulin-treated (A); NIH3T3 insulin-treated (B) whole cell lysates.
Western blot analysis of GSK3 alpha expression in Jurkat (A); HeLa (B); Raw264.7 (C); PC12 (D) whole cell lysates.
Immunohistochemical analysis of GSK3 alpha staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
Immunofluorescent analysis of GSK3 alpha staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 ��C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).
Western blot analysis of extracts from K562/HepG2/RAW264.7 cells, using GSK3 alpha (Ab-21) Antibody.The lane on the right is treated with the synthesized peptide.
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using GSK3 alpha (Ab-21) Antibody.The picture on the right is treated with the synthesized peptide.
WB using Anti-GSK3A antibody shows detection of a 52 kDa band corresponding to human GSK3A in various human derived 293T cell extracts. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Primary antibody was used at 1:1,000.
WB using Anti-GSK3A antibody shows detection of a 52 kDa band corresponding to human GSK3A present in ~ 35 µg of HEK293 whole cell lysate (lane 1). Primary antibody was used at a 1:1,000 dilution in blocking buffer and reacted overnight at 4?. The membrane was washed and reacted with a 1:10,000 dilution of IRDye800™ conjugated Gt-a-Rabbit IgG [H&L] MX for 45 min at RT. Molecular weight estimation was made by comparison to prestained MW markers in lane M (700 nm channel, red).
Predicted cell location: Cytoplasm, Nucleus. Positive control: Human colon and ovarian cancer tissue. Recommended dilution: 1/50-200 The image on the left is immunohistochemistry of paraffin-embedded Human colon and ovarian cancer tissue using GSK3A antibody at dilution 1/50, on the right is treated with the synthetic peptide. (Original magnification:x200)
Predicted cell location: Cytoplasm, Nucleus. Positive control: Human colon and ovarian cancer tissue. Recommended dilution: 1/50-200 The image on the left is immunohistochemistry of paraffin-embedded Human colon and ovarian cancer tissue using GSK3A antibody at dilution 1/50, on the right is treated with the synthetic peptide. (Original magnification:x200)
Predicted cell location: Cytoplasm. Positive control: Human colon and renal cancer tissue. Recommended dilution: 1/50-200 The image on the left is immunohistochemistry of paraffin-embedded Human colon and renal cancer tissue using GSK3A antibody at dilution 1/50, on the right is treated with the synthetic peptide. (Original magnification:x200)
Predicted cell location: Cytoplasm. Positive control: Human colon and renal cancer tissue. Recommended dilution: 1/50-200 The image on the left is immunohistochemistry of paraffin-embedded Human colon and renal cancer tissue using GSK3A antibody at dilution 1/50, on the right is treated with the synthetic peptide. (Original magnification:x200)
Mouse Gsk3a Antibody (C-term) (Cat. #TA324569) western blot analysis in mouse NIH-3T3 cell line lysates (35ug/lane).This demonstrates the Gsk3a antibody detected the Gsk3a protein (arrow).
Mouse Gsk3a Antibody (C-term) (TA324569)immunohistochemistry analysis in formalin fixed and paraffin embedded mouse lymph node(mandibular) followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of Mouse Gsk3a Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.
Western blot analysis of GSK3A (arrow) using GSK3A Antibody (C-term) (Cat.#TA325026). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the GSK3A gene (Lane 2) (Origene Technologies).
GSK3A Antibody (C-term) (Cat. #TA325026) western blot analysis in A549 cell line lysates (35ug/lane).This demonstrates the GSK3A antibody detected the GSK3A protein (arrow).
Western blot analysis of GSK3 alpha expression in ovarycancer whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot analysis of GSK3 lpha/beta expression in TNF-a treated 293 whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot analysis of GSK3 alpha/ beta phosphorylation expression in HeLa whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot analysis of GSK3 alpha phosphorylation expression in ovarycancer whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Predicted band size: 51 kDa . Positive control: 293 cells untreated or treated with serum lysate. Recommended dilution: 1/ 500-1000. (Gel: 10%SDS-PAGE Lane1: 293 cells untreated with serum lysate Lane2: 293 cells treated with serum lysate Lysates: 30 ug per lane Primary antibody: 1/500 dilution Secondary antibody: Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution Exposure time: 1 minute)
Predicted cell location: Cytoplasm. Positive control: Human breast carcinoma tissue. Recommended dilution: 1/ 50-100 The image on the left is immunohistochemistry of paraffin-embedded human breast carcinoma tissue using GSK3A (Phospho-Ser21) antibody at dilution 1/50, on the right is treated with the synthetic peptide. (Original magnification:x200)
Predicted cell location: Cytoplasm. Positive control: Hela cells. Recommended dilution: 1/ 100-200 The image is immunofluorescence of methanol-fixed Hela cells using GSK3A (Phospho-Ser21) antibody at dilution 1/100. (Original magnification:×200)
- Quick-Filters:
- Highly Validated (2)
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| AP02551PU-N | GSK3 alpha antibody |
||||||
 |
Rabbit | Aff - Purified | Hu, Ms, Rt | ICC/IF, P, WB |
0.1 ml /
€320.00
|
||
| Acris Antibodies GmbH | |||||||
 +3 additional images |
Highly validated antibody! |
||||||
| AP02551PU-S | GSK3 alpha antibody |
||||||
|
Rabbit | Aff - Purified | Hu, Ms, Rt | ICC/IF, P, WB |
50 µl /
€240.00
|
||
| Acris Antibodies GmbH | |||||||
| +3 additional images |
Highly validated antibody! |
||||||
| TA312686 | GSK3 alpha antibody |
||||||
| Rabbit polyclonal GSK3a (Ab-21) antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, IP, P, WB |
0.1 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA319231 | GSK3 alpha pSer21 antibody |
||||||
| Rabbit polyclonal GSK3 Alpha phospho S21 antibody | |||||||
 |
Rabbit | Aff - Purified | Hu | E, WB |
0.1 mg /
€356.00
|
||
| OriGene Technologies, Inc. | |||||||
| TA319232 | GSK3 alpha antibody |
||||||
| Rabbit polyclonal GSK3 Alpha antibody | |||||||
![WB using Anti-GSK3A antibody shows detection of a 52 kDa band corresponding to human GSK3A present in ~ 35 µg of HEK293 whole cell lysate (lane 1). Primary antibody was used at a 1:1,000 dilution in blocking buffer and reacted overnight at 4?. The membrane was washed and reacted with a 1:10,000 dilution of IRDye800™ conjugated Gt-a-Rabbit IgG [H&L] MX for 45 min at RT. Molecular weight estimation was made by comparison to prestained MW markers in lane M (700 nm channel, red).](https://m1.acris-antibodies.com/catalog/product/cache/1/small_image/50x50/9df78eab33525d08d6e5fb8d27136e95/OriGene/600-401-444-1-W.jpg) |
Rabbit | Aff - Purified | Hu | E, WB |
0.1 mg /
€356.00
|
||
| OriGene Technologies, Inc. | |||||||
| TA322275 | GSK3 alpha antibody |
||||||
| Anti-GSK3A (Phospho-Ser21) Rabbit Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | ICC/IF, P, WB |
0.1 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| +2 additional images |
|||||||
| TA322276 | GSK3 alpha antibody |
||||||
| Anti-GSK3A Rabbit Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, P |
0.1 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA322277 | GSK3 alpha antibody |
||||||
| Anti-GSK3A Rabbit Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, P |
0.1 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA324569 | GSK3 alpha antibody |
||||||
| Rabbit polyclonal Mouse Gsk3a Antibody (C-term) | |||||||
 |
Rabbit | IgG | Purified | Ms | P, WB |
0.4 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA325026 | GSK3 alpha (C-term) antibody |
||||||
| Rabbit polyclonal GSK3 alpha (GSK3A) Antibody (C-term) | |||||||
 |
Rabbit | Ig | Purified | Hu | P, WB |
0.4 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA326024 | GSK3 alpha antibody |
||||||
| Rabbit Polyclonal GSK3 alpha Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA326025 | GSK3 alpha antibody |
||||||
| Rabbit Polyclonal GSK3 alpha/beta Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA326026 | GSK3 alpha antibody |
||||||
| Rabbit Polyclonal GSK3 alpha (Ser21) Antibody (Phospho-specific) | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA326027 | GSK3 alpha antibody |
||||||
| Rabbit Polyclonal GSK3 alpha/ beta (Tyr279/216) Antibody (Phospho-specific) | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€325.00
|
|
| OriGene Technologies, Inc. | |||||||
| AM00064PU-N | GSK3 alpha (incl. pos. control) antibody |
||||||
 |
Mouse | IgG1 | 10C1 | Purified | Can, Hu, Ms, Rt | WB |
0.1 mg /
€430.00
|
| Acris Antibodies GmbH | |||||||
| AM00065PU-N | GSK3 alpha pSer21 (incl. pos. control) antibody |
||||||
 |
Mouse | IgG1 | 9B8 | Purified | Can, Hu, Ms, Rt | E, WB |
0.1 mg /
€430.00
|
| Acris Antibodies GmbH | |||||||
| AM05356PU-N | GSK3 alpha (+ beta) antibody |
||||||
 |
Mouse | IgG2a | Purified | Hu, Ms, Rt | E, IP, WB |
0.1 mg /
€530.00
|
|
| Acris Antibodies GmbH | |||||||
| AM06171SU-N | GSK3 alpha antibody |
||||||
 |
Mouse | IgG1 | 9D5G1 | Ascites | Hu | ICC/IF, WB |
0.1 ml /
€400.00
|
| Acris Antibodies GmbH | |||||||
| +1 additional image |
|||||||
| AM06172SU-N | GSK3 alpha antibody |
||||||
 |
Mouse | IgG1 | 6G12C2 | Ascites | Hu | WB |
0.1 ml /
€400.00
|
| Acris Antibodies GmbH | |||||||
| AM08183HR-N | GSK3 alpha antibody |
||||||
 |
Mouse | IgG2a | SBGSK3a1 | HRP | Hu, Ms, Rt | WB |
1 ml /
€470.00
|
| Acris Antibodies GmbH | |||||||
